HOWL
Werewolf Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.97
+2.38%Aug 21, 2026, 12:00 UTC
Werewolf Therapeutics and Ambros Therapeutics announced an oversubscribed $150 million private placement in connection with their merger agreement.
Aug 21, 2026, 12:00 UTC
Werewolf Therapeutics and Ambros Therapeutics announced a definitive all-stock merger agreement to combine the companies, with the combined company to operate as Ambros Therapeutics and focus on neridronate for CRPS-1.
Jul 31, 2026, 00:00 UTC
Werewolf Therapeutics reported Q2 2026 financial results with revenue of $21.0 million and net income of $3.7 million, compared to a net loss of $18.0 million in Q2 2025.